A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs INCB 54329 (Primary)
  • Indications Acute myeloid leukaemia; Leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
  • Focus Adverse reactions
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 17 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 31 Jan 2018.
    • 30 Oct 2017 Initial results (n=54) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
    • 01 Aug 2017 According to an Incyte Corporation media release, data expected to be presented at medical meetings in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top